Terns Pharmaceuticals Inc
TERN
Market Cap$265.5M
Close$
$2.01
33.8% downside
Current Fair Value
33.8% downsideOvervalued by 33.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $265.50 Million |
|---|---|
| Enterprise Value | $105.41 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.12 |
| Beta | -0.17 |
| Outstanding Shares | 91,240,700 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.12 |
|---|---|
| PEG | 11.88 |
| Price to Sales | - |
| Price to Book Ratio | 1.01 |
| Enterprise Value to Revenue | 79.74 |
| Enterprise Value to EBIT | -1.05 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Terns Pharmaceuticals Inc
30 employeesTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chr...